IGHE and neoplasm: Olteanu et al. [87] and Linderoth et al. [88] noted a significantly higher survival rate in patients with lymphoma whose cancer cells expressed CD23, compared to those that were CD23-negative: not only suggesting that IgE binding to tumour cells may drive tumour inhibition or killing, but also further suggesting a role for IgE in circulatory immunosurveillance.